Premium
Survival and treatment outcome of head and neck cancer patients with pulmonary oligometastases
Author(s) -
Lardinois Ines,
Dequanter Didier,
Lechien Jérôme R.,
Bouland Cyril,
Javadian Rokneddine,
Rodriguez Alexandra,
Loeb Isabelle,
Journe Fabrice,
Saussez Sven
Publication year - 2021
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/coa.13668
Subject(s) - medicine , metastasis , oncology , chemotherapy , lung cancer , head and neck squamous cell carcinoma , lung , retrospective cohort study , cancer , head and neck cancer , surgery
Objectives The purpose of this study was to determine the outcome of head and neck squamous cell carcinoma (HNSCC) patients developing lung metastasis. Design Retrospective study. Participants HNSCC patients with lung metastasis treated between 2001 and 2018 were included. Mean outcomes measures Statistical analyses described the relationship between patient survival, treatment efficacy and pulmonary metastasis occurrence. Results One hundred HNSCC patients were included in the study. The median overall survival (OS) was 21 months. The median recurrence‐free survival (RFS) was seven months. Patient survival with only lung metastases was significantly longer compared to patients with lung metastases and lymph nodes involvement or other metastases. Moreover, patients with a single metastasis had longer post‐RFS and OS than patients with multiple metastases. The local control of metastasis was better when patients presented only lung metastases, and it was more effective in single metastasis. The surgery allowed better metastases local control than supportive care or radio and/or chemotherapy. In case of specific therapy, pulmonary resection was associated with a longer post‐RFS and a longer OS compared to supportive care or radio and/or chemotherapy. Conclusions We confirmed, in the current study, the significant survival benefit for HNSCC patients treated by surgery for their pulmonary metastasis. While treatment of multiple metastases required palliative chemotherapy or best supportive care in most of the cases, specific surgical treatment in selected HNSCC patients should be considered.